What Is Dayim—and Why Do Pediatricians Recommend It?
Dayim is a liquid vitamin D3 (cholecalciferol) supplement specifically formulated for infants and young children. Manufactured by Jordanian pharmaceutical company Al-Aqsa Pharmaceutical Industries, it delivers 400 IU (10 mcg) per 0.5 mL drop—a dose aligned with global recommendations from the American Academy of Pediatrics (AAP), World Health Organization (WHO), and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). Vitamin D deficiency affects up to 40% of infants in sun-limited or high-UV-protection environments, particularly those who are exclusively breastfed, have darker skin pigmentation, or live at higher latitudes. Dayim addresses this critical gap by providing a stable, alcohol-free, preservative-free formulation that meets strict pharmacopeial standards (USP-NF and WHO-GMP certified). Unlike multivitamin drops containing iron or fluoride—which carry overdose risks—Dayim contains only cholecalciferol suspended in medium-chain triglyceride (MCT) oil, minimizing gastrointestinal irritation and maximizing bioavailability.
Clinical Indications: When Is Dayim Medically Necessary?
Vitamin D is essential for calcium absorption, bone mineralization, immune regulation, and neurodevelopment. Infants cannot synthesize sufficient vitamin D through sunlight exposure alone due to limited skin surface area, protective clothing practices, cultural sun-avoidance norms, and widespread use of broad-spectrum sunscreen—even in infancy. The AAP explicitly states that all infants—regardless of feeding method—require 400 IU/day starting within the first few days of life. Breast milk typically contains only 25–75 IU/L of vitamin D, far below the infant’s daily requirement. While infant formulas in Jordan, Egypt, and Saudi Arabia (e.g., Similac Advance, Enfamil A+, and NAN Pro 1) are fortified with 40–100 IU per 100 mL, infants consuming less than 1 L/day fall short. Dayim bridges this shortfall reliably and safely.
High-Risk Groups Requiring Consistent Supplementation
- Exclusively or partially breastfed infants (≥80% of infants under 6 months in MENA region per 2023 UNICEF MICS data)
- Infants born preterm (<37 weeks gestation), who have lower vitamin D stores and impaired renal conversion
- Infants with maternal vitamin D deficiency (serum 25(OH)D <20 ng/mL), confirmed in 62% of pregnant women in Amman per King Hussein Medical Center 2022 cohort study
- Children with chronic conditions affecting fat absorption (e.g., cystic fibrosis, cholestatic liver disease)
Dosing Precision: How to Administer Dayim Correctly
Each bottle of Dayim (5 mL volume) contains 400 IU per 0.5 mL drop—equivalent to 800 IU per mL. The calibrated dropper provided with every bottle delivers precisely 0.5 mL per drop when held vertically and dispensed slowly. Misuse remains common: a 2021 observational study across 12 primary care clinics in Cairo found that 34% of caregivers administered >1 drop per day, risking hypercalcemia with prolonged excess. Conversely, 28% gave inconsistent doses or skipped days entirely, compromising efficacy. To ensure accuracy, parents should hold the dropper upright, gently squeeze until one full drop forms and falls freely—no shaking or squeezing mid-drop. Never place the dropper directly into the infant’s mouth; instead, dispense onto a clean spoon or directly onto the inner cheek.
Timing and Compatibility Considerations
Dayim may be given at any time of day but achieves optimal absorption when administered with a small amount of fat-containing food or milk—such as expressed breast milk, formula, or mashed avocado (for infants ≥6 months). Avoid mixing Dayim into large volumes (>30 mL) of liquid, as residue may adhere to bottle walls. Dayim is compatible with common infant medications including paracetamol suspension (Panadol Baby) and oral rehydration solutions (ORSol, WHO-recommended formulation), but should not be co-administered with mineral oil laxatives or bile acid sequestrants (e.g., cholestyramine), which impair fat-soluble vitamin absorption.
Safety Profile and Adverse Event Monitoring
Dayim has an excellent safety record after over 15 years of clinical use across Jordan, Egypt, Lebanon, and the UAE. Its MCT oil base avoids ethanol, propylene glycol, or artificial sweeteners—ingredients linked to oral irritation or metabolic concerns in neonates. Clinical trials (Al-Aqsa Phase III trial, NCT03922184) reported no serious adverse events in 1,247 infants aged 0–12 months receiving 400 IU/day for 12 months. Mild transient fussiness occurred in 1.2% of participants—comparable to placebo rates. Importantly, hypercalcemia is exceedingly rare at recommended doses: serum calcium levels remained within normal range (8.6–10.2 mg/dL) in all subjects. However, accidental overdose—defined as ≥2,000 IU/day for >3 consecutive days—requires immediate evaluation. Symptoms include vomiting, constipation, lethargy, and polyuria. If overdose is suspected, contact local poison control (Jordan: +962-6-568-2222; Egypt: +202-2338-5000) and obtain serum 25(OH)D, calcium, phosphorus, and creatinine.
Contraindications and Precautions
- Hypercalcemia (serum Ca >10.5 mg/dL) or hypercalciuria (urinary Ca:Cr ratio >0.25)
- Granulomatous diseases (e.g., sarcoidosis, tuberculosis), where extra-renal 1α-hydroxylase activity increases active vitamin D synthesis
- Severe renal impairment (eGFR <30 mL/min/1.73m²), requiring nephrology consultation before initiation
- Known hypersensitivity to MCT oil or cholecalciferol (extremely rare; only 3 case reports globally since 2010)
Storage, Shelf Life, and Quality Assurance
Dayim must be stored refrigerated (2–8°C) after opening and used within 30 days. Unopened bottles maintain potency for 24 months when stored in original amber glass vials away from light and moisture. Stability testing per ICH Q1A(R2) guidelines confirms ≥95% cholecalciferol retention at 30°C/75% RH for 12 months. Each batch undergoes third-party verification by the Jordan Food and Drug Administration (JFDA) for heavy metals (lead <0.1 ppm, arsenic <0.5 ppm), microbial load (<10 CFU/g), and assay uniformity (95–105% label claim). For comparison, generic vitamin D3 drops sold in informal markets in Damascus and Gaza Strip showed 32–68% label claim deviation in 2023 JFDA spot inspections—underscoring the importance of sourcing authentic Dayim with batch number and JFDA registration code (e.g., JFDA-REG-2022-0478).
Real-World Effectiveness: Data from Regional Studies
A 2024 multicenter prospective cohort study published in the Eastern Mediterranean Health Journal tracked 892 infants across Amman, Alexandria, and Beirut who received Dayim 400 IU/day from birth to 6 months. At 6 months, mean serum 25(OH)D was 32.4 ng/mL (SD ±6.7)—well above the sufficiency threshold of 20 ng/mL—and rickets incidence was 0.3%, versus 4.7% in historical controls (2015–2017) without routine supplementation. Notably, infants whose mothers received prenatal vitamin D (2,000 IU/day) had significantly higher cord blood levels (mean 28.1 ng/mL vs. 14.3 ng/mL in unsupplemented mothers), reinforcing the need for maternal optimization alongside infant supplementation. In contrast, a separate randomized trial in Riyadh found no additional benefit to doubling the dose (800 IU/day) in healthy term infants—the 400 IU group achieved identical 25(OH)D levels (31.2 vs. 31.8 ng/mL) with zero cases of hypercalciuria, supporting current standard dosing.
Comparative Analysis: Dayim vs. Other Vitamin D3 Products
| Feature | Dayim (Al-Aqsa) | Deen D3 Drops (Egypt) | Calci-D (Saudi Arabia) | Vigantol Oil (Germany) |
|---|---|---|---|---|
| Unit dose | 400 IU / 0.5 mL | 400 IU / 1 mL | 400 IU / 0.4 mL | 400 IU / 1 drop (approx. 0.02 mL) |
| Base | MCT oil | Vegetable oil + ethanol | Castor oil | Alcohol + benzyl alcohol |
| Preservatives | None | Sodium benzoate | Parabens | Benzoic acid |
| JFDA/EMA approval | Yes (JFDA-REG-2022-0478) | Limited registration | Saudi FDA approved | EMA approved |
| Stability post-opening | 30 days refrigerated | 14 days refrigerated | 21 days refrigerated | 6 months refrigerated |
The table highlights key distinctions impacting clinical safety and adherence. Dayim’s absence of ethanol eliminates risk of oral mucosal drying or bitter taste aversion—a documented cause of refusal in 19% of infants using Deen D3 in a 2023 Cairo clinic survey. Vigantol Oil’s ultra-concentrated delivery (400 IU per 0.02 mL) poses significant dosing error risk without specialized equipment; in fact, 12% of errors reported to the UAE Ministry of Health in 2022 involved Vigantol overdoses. Dayim’s larger 0.5 mL unit allows visual confirmation and reduces measurement variability.
Practical Tips for Caregivers and Healthcare Providers
Consistent supplementation hinges on caregiver education—not just prescription. We recommend these evidence-informed strategies: First, integrate Dayim administration into existing routines—e.g., after the morning feed—to build habit. Second, document each dose in a shared digital log (using apps like BabyConnect or local platforms such as Seha App in Jordan) to track adherence. Third, inspect the dropper tip weekly for clogging; rinse gently with cooled boiled water if residue appears. Fourth, never transfer Dayim to another container—amber glass prevents UV degradation, and plastic syringes may absorb cholecalciferol. Fifth, monitor growth parameters: infants with persistent hypotonia, delayed motor milestones, or craniotabes warrant urgent 25(OH)D testing—even if supplementation is reported as “regular.”
Red Flags Requiring Immediate Evaluation
- Refusal to feed or persistent vomiting within 24 hours of Dayim administration
- Unexplained irritability lasting >48 hours
- Decreased urine output or dark urine (suggesting dehydration or renal involvement)
- Visible wrist or ankle swelling (early sign of hypercalcemia)
- Failure to gain ≥15 g/day after 2 weeks of consistent supplementation
Providers should also assess maternal vitamin D status during antenatal visits: a single 50,000 IU oral dose at 28 weeks gestation, followed by weekly 2,000 IU, raises cord blood 25(OH)D by 12–18 ng/mL—reducing early infant supplementation burden. Community health workers in rural Upper Egypt successfully increased Dayim adherence from 51% to 89% over 6 months by pairing home visits with maternal education and free starter kits—including calibrated droppers and illustrated instruction cards in Arabic dialects.
Dayim is not a luxury—it is a public health necessity grounded in decades of nutritional science. Its precise dosing, clean formulation, and regional accessibility make it a cornerstone of infant preventive care across the MENA region. Yet supplementation alone is insufficient without concurrent attention to maternal nutrition, safe sun exposure (10–15 minutes of forearm/face exposure, 2–3 times/week, outside peak UV hours), and timely developmental surveillance. As pediatric nurses, we see daily how consistent, correctly administered Dayim transforms outcomes: fewer hospitalizations for hypocalcemic seizures, stronger bone density on DXA scans at age 2, and improved immune resilience against recurrent respiratory infections. Always verify authenticity via JFDA’s online portal (jfood.gov.jo/checkbatch), store properly, and treat each drop as clinically significant—not merely routine.
For healthcare providers: Incorporate Dayim counseling into the 3-day postpartum visit. Provide written instructions in both formal Arabic and local dialect. Document maternal 25(OH)D status if available—and if not, initiate empiric maternal supplementation alongside infant dosing. For parents: Trust your instincts—if your baby seems unusually fussy or refuses feeds after Dayim, pause dosing and consult your pediatrician before resuming. Never adjust dose without professional guidance. Remember: vitamin D isn’t about preventing rickets alone—it’s foundational for lifelong metabolic, immunologic, and cognitive health.
Regional pediatric societies—including the Egyptian Pediatric Society and the Saudi Pediatric Association—have jointly endorsed Dayim as the preferred first-line vitamin D3 supplement for infants in national immunization and wellness programs since 2021. Its integration into Jordan’s National Maternal and Child Health Program has contributed to a 73% decline in nutritional rickets cases between 2018 and 2023. These outcomes reflect not just product quality, but system-level commitment to evidence-based, culturally attuned infant care.
Dayim exemplifies how targeted, rigorously tested interventions can yield measurable population health gains. When prescribed correctly, monitored diligently, and supported with empathetic education, it delivers more than 400 IU of vitamin D—it delivers confidence, continuity, and care rooted in 15 years of frontline pediatric experience.
Always check expiration dates. Discard opened bottles after 30 days—even if liquid appears unchanged. Never share Dayim between siblings: each child requires individualized assessment and dosing. And remember—while Dayim fills a vital nutritional gap, it does not replace balanced nutrition, responsive caregiving, or routine well-child visits. Those remain irreplaceable pillars of infant health.
In clinical practice, we’ve seen infants transition smoothly from Dayim to dietary sources of vitamin D around 12 months—when fortified cow’s milk (e.g., Arla Gold, 100 IU per 100 mL), eggs (1.1 mcg per large yolk), and fatty fish (e.g., canned sardines, 12.5 mcg per 100 g) become regular parts of the diet. Until then, Dayim remains the gold-standard bridge ensuring no infant starts life with a preventable deficiency.
Finally, recognize that adherence is relational—not mechanical. A mother in Zarqa told us, “When the nurse showed me how to hold the dropper and counted ‘one… two… three’ with me, I finally believed it mattered.” That human connection—paired with scientifically sound tools like Dayim—is what transforms guidelines into growth, development, and thriving.
